 SAN DIEGO, June 10, 2021 PRNewswire -- Aethlon Medical, Inc. Nasdaq:AEMD, a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct offering of 1,380,555 shares of its common stock, at a purchase price per share of 9.00, priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 14, 2021, subject to the satisfaction of customary closing conditions. 